Sub-millimetric, patient-specific brain targeting for functional neurosurgery and real-world outcomes in Parkinson’s Disease and Essential Tremor.

Les Echos Highlights RebrAIn’s AI Innovations in Parkinson’s Disease Treatment

We are thrilled to announce that Les Echos has featured RebrAIn for our innovative application of supervised AI in the treatment of Parkinson’s Disease.

The article explores how our AI-driven solutions are revolutionizing Deep Brain Stimulation (DBS) by enhancing precision and patient outcomes. Co-founded by Professor Emmanuel Cuny and Dr. Nejib Zemzemi, RebrAIn continues to push the boundaries of neurosurgical technology.

Learn more about our groundbreaking work by reading the full article in french on Les Echos.

An English translation by Google is available here.

Our latest public updates

Rebrain x Worldwide Dystonia Research Center

Rebrain x Worldwide Dystonia Research Center

Partnership aims to develop next-generation data-driven models for personalized deep brain stimulation (DBS) targeting, expanding clinical applications from Parkinson’s disease and essential tremor to dystonia and severe pediatric dystonia with global scalability...

RebrAin 2025/2026: Expanding Reach, Driving Innovation

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...